Page 25 - WCMS1Q22

Michigan.gov/CovidTherapy Michigan.gov/CovidTherapy
Purpose: Provide a clinically focused overview of outpatient therapies for mild to moderate Updated 2-23-22
COVID-19 in patients at risk for hospitalization or death at a time when the demand for these Updated 2-23-22
therapies meets or exceeds available supply. Guidelines may be adjusted should another surge
Purpose: Provide a clinically focused overview of outpatient therapies for mild to moderate cause an increased demand for therapeutics.
PurpoCseO:VPIrDo-v1i9dienapactliienitcsaltlyrisfkocfoursheodspoivtaelrizvaiteiwon ofr doeuattphaattieanttimtheewrahpeinetshfeodremailnd tformthoedserate therapies meets or exceeds available supply. Guidelines may be adjusted should another surge
COVID-19 in patients at risk for hospitalization or death at a time when the demand for these
Background: Since November 2020, options for outpatient therapies for patients with mild to cause an increased demand for therapeutics.
therapies meets or exceeds available supply. Guidelines may be adjusted should another surge moderate COVID-19 have become increasingly available. These include monoclonal antibody
hospitals, urgent care, and primary care providers. To help communicate with the public,
hospitals, urgent care, and primary care providers. To help communicate with the public, saving medications and consider their use when clinically indicated.
MDHHS has developed an Ongoing Response to the COVID-19 cycle recognizing the ability to MDHHS has developed an Ongoing Response to the COVID-19 cycle recognizing the ability to
flex mfleixtigmaitigoantsiomnsemaseuasruerseasnadndththeerrapeuticssbbaasesdedonotnhethsetastutastoufsCoOfVCIODVinIDa cionmamcuonmitym, unity, Throughout this pandemic, the number of patients presenting for care has caused a surge at
regiorne,giaond, atnhdetshteatseta.teT.hTeheCCOOVVIID--19 cyclleeisisbbrorkoekneintionthoretherkeeykpehyaspesh:ases:
hospitals, urgent care, and primary care providers. To help communicate with the public,
v
• Response – local and state public health implement rapid response to a surge. The public
• Response – local and state public health implement rapid response to a surge. The public
MDHHS has developed an Ongoing Response to the COVID-19 cycle recognizing the ability to may be advised to increase masking, testing, social distancing, and use of outpatient
may be advised to increase masking, testing, social distancing, and use of outpatient flex mitigations measures and therapeutics based on the status of COVID in a community,
• • •
• •
Recovery- this is post surge. No immediate resurgence predicted. Local and state public Response – local and state public health implement rapid response to a surge. The public
therapeutics.
therapeutics.
region, and the state. The COVID-19 cycle is broken into three key phases:
• Recovery- this is post surge. No immediate resurgence predicted. Local and state public
health will monitor conditions that could lead to future surges. Clinicians should continue
health will monitor conditions that could lead to future surges. Clinicians should continue maybtoeiaddevnitisfeydptaotieintcsrweahsoemayasbkeinegfi,ttfersotminogu,tspoatciieanltdthiesrtapniceisn.g,anduseofoutpatient
to identify patients who may benefit from outpatient therapies. the•rapReeuatdicinse.ss- A surge in cases is expected, with implications on severity of illness and
Reahdoinspeistasl-cAapsaucirtgye. Linoccaalsaensdistaetexpeucbtliecdh,ewalitthwimorpkltiocaetnisounreseonousgehvesruiptyplioefsiolflntests,and Recovery- this is post surge. No immediate resurgence predicted. Local and state public
masks and medications are available. Increased communications to the public regarding hospital capacity. Local and state public health work to ensure enough supplies of tests, health will monitor conditions that could lead to future surges. Clinicians should continue
possible new risks. Increased communications with clinicians should modification of
masks and medications are available. Increased communications to the public regarding
to identify patients who may benefit from outpatient therapies. eligibility criteria for COVID therapeutics be necessary.
possible new risks. Increased communications with clinicians should modification of Readiness- A surge in cases is expected, with implications on severity of illness and
eligibility criteria for COVID therapeutics be necessary.
hospital capacity. Local and state public health work to ensure enough supplies of tests,
masks and medications are available. Increased communications to the public regarding possible new risks. Increased communications with clinicians should modification of eligibility criteria for COVID therapeutics be necessary.
For more information, visit Michigan.gov/Coronavirus For more information, visi
COVID-19 OUTPATIENT THERAPY
Guidance for outpatient therapies for patients with mild to moderate COVID-19
patients with mild to modera -19
Updated 2-23-22
Michigan.go
COVID-19 OUTPATIENT THERAPY COVID-19 OUTPATIENT THERAPY
Guidance for outpatient therapies for Guidance for outpatient therapies for
patients with mild to moderate C
/CovidTherapy
te COVID OVID-19
cause an increased demand for therapeutics. (mAbB)atchkegraopuynda:nSdi,nmceoNreovremcebnetrl2y0,2o0r,aolpatniotnivsifroarlotuhtepraatipeyn.t Cthoerlalepcietsivfeolryp,athieenstes wmitehdmicialdtiotons have
moderate COVID-19 have become increasingly available. These include monoclonal antibody prevented thousands of hospitalizations and deaths in Michigan. Until recently, these
Background: Since November 2020, options for outpatient therapies for patients with mild to (mAb) therapy and, more recently, oral antiviral therapy. Collectively, these medications have
medications have often been in limited supply, necessitating prioritizing eligibility to those at moderaptrevCenOteVdItDho-u1s9anhdasvoefbheocspoimtaleizianticornesaasnindgdleyatahvsaiinlaMbliceh.iTgahne.sUenitnilcrleucdeentmlyo,tnhoecselonalantibody
higher risk. As current COVID-19 activity declines and with increasing medication supply, there (mAb)mthedeircaaptiyonasnhda,vme ofrtenrebceentilny,liomriateldansutipvpilrya,lntehcersasiptayt.inCgoplrlieocrittiivzeinlgy,etlihgeibseilimtyetoditchaotsieoants have
is no longer a need for limiting eligibility beyond the requirements established by the Food and
higher risk. As current COVID-19 activity declines and with increasing medication supply, there prevented thousands of hospitalizations and deaths in Michigan. Until recently, these
Drug Administration (FDA). In the event of future COVID-19 surges and/or reductions in is no longer a need for limiting eligibility beyond the requirements established by the Food and
medications have often been in limited supply, necessitating prioritizing eligibility to those at supplDyr,upgrAiodrmitinziastiroatniomn a(FyDnAe)e.dIntothbeevrenetsotafbfulitsuhredC.OHVoIwD-e1v9esru,ragtetshainsdt/iomr reedituicstioimnspionrtant that all higher risk. As current COVID-19 activity declines and with increasing medication supply, there
clinicsiuapnpslyc, aprinogritfizoartiConOmVaIyDn-e1e9d ptoatbienretessbtaeblaiswheadre. Hoofwtheevearv, atiltahbisiltimtyeoitf itshiemspeoirmtapntotrhtatnatllife-
is no longer a need for limiting eligibility beyond the requirements established by the Food and
clinicians caring for COVID-19 patients be aware of the availability of these important life- saving medications and consider their use when clinically indicated.
Drug Administration (FDA). In the event of future COVID-19 surges and/or reductions in saving medications and consider their use when clinically indicated.
supply, prioritization may need to be reestablished. However, at this time it is important that all Throughout this pandemic, the number of patients presenting for care has caused a surge at
cliniciaTnhsrocuagrhinougtftohirsCpaOnVdeImDi-c1, 9thepantuimenbtesrboef paawtieanretsopfretsheentainvgaifloarbcialriteyhoasfcthauesediamspuorgretaantt life-
For more information, visit Michigan.gov/Coronavirus Volume 74 • Number 1 Washtenaw County Medical Society BULLETIN 25
Michigan.gov/Coronavirus
Michigan.gov/Coronavirus
t